FINNENCE ▪ THE WIRE FILE
THE WIRE · № 68998
News■ Unclear/unknown
Lakewood-Amedex Biotherapeutics Announces Positive Preclinical Data in Urinary Tract and Pulmonary Infection Indications with Bisphosphocin® Compounds
KINDNews
DIRECTION■ Unclear/unknown
SOURCES1
ENTITIES1
STORY SIZESTANDALONE
FIRST SEEN2026-10-07 12:02 UTC
LAST UPDATE2026-10-07 12:02 UTC
STATEactive
01 THE MACHINE READ
WHY IT MATTERS.
Preclinical rodent data is years from commercialization and carries no near-term market consequence.
Early-stage biotech data, not investable yet
CATALYST TO WATCH
IND filing or clinical trial initiation
MAIN RISK
Preclinical results often fail in humans
FULL DISPATCH
Intravesical administration of the Bisphosphocin® Nu-8 to rodents infected with E. coli demonstrated up to 97% inhibition of E. coli growth compared to no effect in a vehicle control group. SARASOTA, Fla., Oct. 7, 2026 /PRNewswire/ -- Lakewood-Amedex Biotherapeutics Inc., (NASDAQ: LABT,...
02 THE STORY SO FAR
THE RECORD, IN ORDER.
STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.
03 WHO'S INVOLVED
ENTITIES ON FILE.
AFFECTEDHealthcare
04 RECEIPTS
THE SOURCE RECORD.
1 SOURCES CONFIRMED05 PROPAGATION
WHAT THIS TOUCHES.
→CORRELATIONshares Healthcare
Where to Invest $100,000: Healthcare, AI and High-Quality Bonds2026-10-07 11:00 UTC
Where to Invest $100,000: Healthcare, AI and High-Quality Bonds2026-10-07 11:00 UTC
→CORRELATIONshares Healthcare
Manufacturing Bispecific Antibodies: Development & Scale-Up, Upcoming Webinar Hosted by Xtalks2026-10-07 12:30 UTC
Manufacturing Bispecific Antibodies: Development & Scale-Up, Upcoming Webinar Hosted by Xtalks2026-10-07 12:30 UTC
→CORRELATIONshares Healthcare
FibroBiologics Files Patent Application for Technology Designed to Produce GLP-1 and Other Therapeutic Peptides Inside the Body2026-10-07 12:30 UTC
FibroBiologics Files Patent Application for Technology Designed to Produce GLP-1 and Other Therapeutic Peptides Inside the Body2026-10-07 12:30 UTC
→CORRELATIONshares Healthcare
Why CVOTs Require a Different Approach: Optimizing Event Accrual to Reduce Trial Delays, Upcoming Webinar Hosted by Xtalks2026-10-07 12:30 UTC
Why CVOTs Require a Different Approach: Optimizing Event Accrual to Reduce Trial Delays, Upcoming Webinar Hosted by Xtalks2026-10-07 12:30 UTC
→CORRELATIONshares Healthcare
AbbVie's Telisotuzumab Adizutecan (Temab-A) Receives Two Breakthrough Therapy Designations From the U.S. FDA for CRC and NSCLC2026-10-07 12:30 UTC
AbbVie's Telisotuzumab Adizutecan (Temab-A) Receives Two Breakthrough Therapy Designations From the U.S. FDA for CRC and NSCLC2026-10-07 12:30 UTC
→CORRELATIONshares Healthcare
Resonant Clinical Solutions and Haier Biomedical Introduce an Innovative Benchtop Centrifuge with a Natural Refrigerant2026-10-07 12:30 UTC
Resonant Clinical Solutions and Haier Biomedical Introduce an Innovative Benchtop Centrifuge with a Natural Refrigerant2026-10-07 12:30 UTC
KEEP READING THE MACHINE
Summaries are generated and may contain errors — every claim links its sources.